These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11195537)

  • 1. [The influence of alpha-dihydroergocryptine derivatives on psychomotor manifestations in Parkinson disease].
    Sadekov RA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):43-5. PubMed ID: 11195537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preventive treatment of migraine with vasobral: a multicenter trial].
    Tabeeva GR; Azimova IuE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 2):26-30. PubMed ID: 21389936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of vasobral in therapy of central nervous system pathology in children of early age].
    Zaĭtseva IN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(1):92-4. PubMed ID: 20614656
    [No Abstract]   [Full Text] [Related]  

  • 4. [Vasobral in the treatment of brain lesions: views of physicians and patients].
    Kamchatnov PR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(1):23-5. PubMed ID: 23528488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vasobral and stabilized cerebral vascular complication: hemodynamic and psychometric study].
    Poncin-Lafitte M; Migeon P; Rancurel G; Rapin JR
    Ann Radiol (Paris); 1987; 30(6):425-30. PubMed ID: 3129979
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacy of the combination drug vasobral in chronic vascular encephalopathy].
    Levin OS; Barantsevich ER; Belskaya GN; Vasenina EE; Kopishinskaya SV; Lukashevich IG; Ostroumova OD; Psokhina OV; Radiuk MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(10):25-9. PubMed ID: 25591512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vasobral in the treatment of initial atherosclerotic circulatory encephalopathy].
    Shprakh VV; Molokov DD; Tatarinova MB; Burdukovskaia NL
    Zh Nevrol Psikhiatr Im S S Korsakova; 1996; 96(2):39-40. PubMed ID: 8754338
    [No Abstract]   [Full Text] [Related]  

  • 8. Alpha-dihydroergocryptine in the long-term therapy of Parkinson's disease.
    Mailland E; Magnani P; Ottillinger B
    Arzneimittelforschung; 2004; 54(10):647-54. PubMed ID: 15553103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroergocryptine in the treatment of Parkinson's disease.
    Bonuccelli U; D'Antonio P; D'Avino C; Piccini P; Muratorio A
    J Neural Transm Suppl; 1995; 45():239-45. PubMed ID: 8748631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experience in the administration of vasobral in sensorineural vascular hypoasusis].
    Grinshteĭn AB; Shnaĭder NA; Kromm OK; Pavlovskaia MV
    Vestn Otorinolaringol; 2001; (2):39-41. PubMed ID: 11338557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S23-37. PubMed ID: 12211137
    [No Abstract]   [Full Text] [Related]  

  • 12. [Inhibition of post-partum physiological milk secretion by caffeine dihydroergocryptine and dihydroergotoxine].
    Elsener M; Ferrafiat M; de Bruyn M; Jouhet P; Robert Y; Rouge PE
    Rev Fr Gynecol Obstet; 1988 Nov; 83(11):697-701. PubMed ID: 3144727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amantadine and other antiglutamate agents: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S13-22. PubMed ID: 12211136
    [No Abstract]   [Full Text] [Related]  

  • 14. Motor fluctuations in Parkinson's disease.
    Crabb L
    Prof Nurse; 2000 Jan; 15(4):273-7. PubMed ID: 10983145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.
    Gunzler SA; Pavel M; Koudelka C; Carlson NE; Nutt JG
    Clin Neuropharmacol; 2009; 32(2):97-102. PubMed ID: 18978495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Parkinson's disease and dopaminergic medication on proprioceptive processing.
    Mongeon D; Blanchet P; Messier J
    Neuroscience; 2009 Jan; 158(2):426-40. PubMed ID: 18996173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of quality of life and treatment adherence in patients with dizziness treated with vasobral].
    Lebedeva AV; Kamchatnov PR; Burd SG; Prikazchikov SV; Cherkasova AE; Solovyeva TY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2):28-34. PubMed ID: 30874523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficiency of new forms of madopar in Parkinson's disease].
    Vendrova MI; Sadekov RA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):46-8. PubMed ID: 11195538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alpha-dihydroergocryptine; experiences--perspectives].
    Nervenarzt; 1996 Mar; 67(3 Suppl):1-8. PubMed ID: 9022394
    [No Abstract]   [Full Text] [Related]  

  • 20. [The use of vasobral in patients with chronic cerebrovascular disorders].
    Kamchatnov PR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(10 Pt 1):70-2. PubMed ID: 22500318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.